Hypertrophic cardiomyopathy (HCM) and arterial hypertension (AH) are characterized by pathologic remodelling of intramural coronary arterioles, which is the substrate of coronary microvascular dysfunction (CMD) and myocardial ischemia, in absence of coronary artery stenosis. In both conditions remodelling consists in vessel wall thickening, due to medial smooth muscle hypertrophy/proliferation and collagen deposition with different degrees of intimal thickening and perivascular fibrosis. The transcriptome associated with dysfunctional coronary microvessels and cardiomyocytes has never been investigated in patients with HCM. Assess the difference in gene expression profile between HCM and normal heart, both in coronary microvessels and cardiomyocytes are necessary to shed light on the pathogenic mechanism of microvascular remodelling. A better understanding of the pathogenesis of coronary microvascular remodelling could lead to the development of novel specific therapies for CMD.

Gene expression profiling and enrichment functional analyses to compare coronary microvessels and cardiomyocytes in patients with hypertrophic cardiomyopathy

Le Pera L;
2020

Abstract

Hypertrophic cardiomyopathy (HCM) and arterial hypertension (AH) are characterized by pathologic remodelling of intramural coronary arterioles, which is the substrate of coronary microvascular dysfunction (CMD) and myocardial ischemia, in absence of coronary artery stenosis. In both conditions remodelling consists in vessel wall thickening, due to medial smooth muscle hypertrophy/proliferation and collagen deposition with different degrees of intimal thickening and perivascular fibrosis. The transcriptome associated with dysfunctional coronary microvessels and cardiomyocytes has never been investigated in patients with HCM. Assess the difference in gene expression profile between HCM and normal heart, both in coronary microvessels and cardiomyocytes are necessary to shed light on the pathogenic mechanism of microvascular remodelling. A better understanding of the pathogenesis of coronary microvascular remodelling could lead to the development of novel specific therapies for CMD.
2020
Istituto di Biologia e Patologia Molecolari - IBPM
Istituto di Biomembrane, Bioenergetica e Biotecnologie Molecolari (IBIOM)
hypertrophic cardiomyopathy
Myocardial disease
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/20.500.14243/405617
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact